Effective therapy regimens for COVID-19 pneumonia in critically ill patients with the development of the cytokine storm syndrome.

Stanislav Viktorovich Serafimov

ПРЕПРИНТ

Эта статья является препринтом и не была отрецензирована.
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.

Effective therapy regimens for COVID-19 pneumonia in critically ill patients with the development of the cytokine storm syndrome.

S. V. Serafimov

2020-07-08

https://doi.org/10.24108/preprints-3112088

The main reason for the development of severe pneumonia in patients with COVID‑19 is apparently injury of the endothelium by the virus and the immune system, which leads to the development of massive microthrombosis. We believe that it is very important to prescribe anticoagulants to COVID-19 patients as early as possible and to administer prolonged low doses of glucocorticoids at certain indicators. These treatment regimens are expected to reduce the mortality caused by COVID‑19. Perhaps it is necessary to be very careful about the administration of IL-6 inhibitors. We assume that the main indicators for the administration of IL-6 inhibitors are the following indicators: CRP > 150 mg/L, IL-6 in the blood > 40 pc/mL, procalcitonin < 0.5 μg/L. To confirm our hypotheses, a large-scale study is required.

Ссылка для цитирования:

Serafimov S. V. 2020. Effective therapy regimens for COVID-19 pneumonia in critically ill patients with the development of the cytokine storm syndrome. PREPRINTS.RU. https://doi.org/10.24108/preprints-3112088

Список литературы

1. Ministry of health of the Russian Federation. 2020. https://minzdrav.gov.ru/ministry/med_covid19

2. Xiaomin Luo, Wei Zhou, Xiaojie Yan, Tangxi Guo, Benchao Wang, Hongxia Xia, Lu Ye, Jun Xiong, Zongping Jiang, Yu Liu, Bicheng Zhang, Weize Yang.2020. Prognostic value of C-reactive protein in patients with COVID-19. Medrxiv.doi:https://doi.org/10.1101/2020.03.21.20040360

3. Xiaomin Luo, MD, Wei Zhou, MD, Xiaojie Yan, MD, Tangxi Guo, MD, Benchao Wang, MD, Hongxia Xia, MD, Lu Ye, MD, Jun Xiong, MD, Zongping Jiang, MD, Yu Liu, MD ... Show more Author Notes. 2020. Prognostic value of C-reactive protein in patients with COVID-19. Clinical Infectious Diseases, ciaa641, https://doi.org/10.1093/cid/ciaa641

4. Javier Martinez-Sanz, Alfonso Muriel, Raquel Ron, Sabina Herrera, Raquel Ron, Jose A Perez-Molina, Santiago Moreno, Sergio Serrano-Villar.2020. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study. Medrxiv.doi:https://doi.org/10.1101/2020.06.08.20125245

5. View ORCID ProfilePeter Horby, View ORCID ProfileWei Shen Lim, View ORCID ProfileJonathan Emberson, View ORCID ProfileMarion Mafham, Jennifer Bell, View ORCID ProfileLouise Linsell, et al.2020. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. Medrxiv. doi: https://doi.org/10.1101/2020.06.22.20137273

6. Sanjiv Jha, Kiran Shetty, Sonali Vadi, Sourabh Phadtare, Vatsal Kothari, Abhijit Raut, Sweta Shah, Pallavi Bhargava, Tanu Singhal.2020. Initial experience with short-course corticosteroids in a small cohort of adults with severe COVID-19 in a tertiary care hospital in India. Medrxiv.doi: https://doi.org/10.1101/2020.06.23.20137471

7. Francesco Salton, Paola Confalonieri, Pierachille Santus, Sergio Harari, Raffaele Scala, Simone Lanini, Valentina Vertui, Tiberio Oggionni, Antonella Caminati, Vincenzo Patruno, Mario Tamburrini, Alessandro Scartabellati, Mara Parati, Massimiliano Villani, Dejan Radovanovic, Sara Tomassetti, Claudia Ravaglia, Venerino Poletti, Andrea Vianello, Anna Talia Gaccione, Luca Guidelli, Rita Raccanelli, Donato Lacedonia, Paolo Lucernoni, Maria Pia Foschino et al.2020. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia.Medrxiv.doi: https://doi.org/10.1101/2020.06.17.20134031

8. Chaomin Wu, MD1,2,3; Xiaoyan Chen, MD3; Yanping Cai, MD2; et al.2020. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med.doi:10.1001/jamainternmed.2020.0994

9. Pratik Sinha, MB, ChB, PhD1,2; Michael A. Matthay, MD1,2,3; Carolyn S. Calfee, MD, MAS1,2,3. 2020. Is a “Cytokine Storm” Relevant to COVID-19?. JAMA Intern Med. doi:10.1001/jamainternmed.2020.3313.

10. Maximilian Ackermann, M.D., Stijn E. Verleden, Ph.D., Mark Kuehnel, Ph.D., Axel Haverich, M.D., Tobias Welte, M.D., Florian Laenger, M.D., Arno Vanstapel, Ph.D., Christopher Werlein, M.D., Helge Stark, Ph.D., Alexandar Tzankov, M.D., William W. Li, M.D., Vincent W. Li, M.D., et al. 2020. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. The New England Journal of Medicine, NEJM.DOI: 10.1056/NEJMoa2015432

11. Villar, Jesús MD, PhD1–3; Confalonieri, Marco MD4; Pastores, Stephen M. MD, MACP, FCCP, FCCM5; Meduri, G. Umberto MD.2020. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019. Critical Care Explorations. doi: 10.1097/CCE.0000000000000111

ПРЕПРИНТ

ИНФОРМАЦИЯ